Biogen Inc.

NASDAQ Global Select
Back to all articles
Bearish -50

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

📉 Biogen's stock has gained 25.5% recently, trading at $183.50, though analysts advise caution despite recent outperformance.

⚠️ The company's demand has been weak over the last five years with sales falling at a 6% annual rate.

📉 EPS declined by 14.2% annually over the same period, indicating shrinking profitability relative to revenue growth.

💸 Return on invested capital (ROIC) has decreased significantly in recent years due to fewer profitable growth opportunities.

🚫 Fixed cost structures have made Biogen difficult to adjust to shrinking demand effectively.

💰 Current valuation at 11.3× forward P/E is considered fair but lacks confidence in future business quality.

🔍 Analysts recommend avoiding BIIB and suggest finding better investment alternatives elsewhere in the market.

🤖 StockStory promotes an AI-driven stock selection system that identified high-growth stocks like Palantir and Nvidia prior to major runs.

📝 The company has been flagged as a digital advertising pick alternative with specific growth potential.

⏳ Investors are advised that the current market is separating quality from expensive stocks rapidly.

Bullish Signals
  • Biogen shares have beaten the S&P 500 by 19.7% over the past six months, demonstrating recent outperformance.
  • The stock has gained 25.5% recently and trades at $183.50 per share, reflecting investor interest and strong short-term momentum.
  • Biogen delivered solid quarterly results that contributed to its impressive run and positive market sentiment.
  • Management has demonstrated a track record of successful decisions in the past, showing prior capability.
  • The stock currently trades at a fair valuation multiple of 11.3× forward P/E, presenting a reasonable entry point for investors.
Risk Factors
  • Biogen's demand was weak over the last five years as its sales fell at a 6% annual rate.
  • The company's earnings per share (EPS) declined by 14.2% annually over the last five years, indicating that incremental sales were not profitable.
  • Biogen's return on invested capital (ROIC) has decreased significantly over the last few years, suggesting fewer profitable growth opportunities.
  • Despite a recent stock price gain, the analysts express low confidence in Biogen and recommend avoiding the stock.
Full Analysis
Biogen (BIIB) has recently seen its shares outperform the S&P 500 by 19.7% over the past six months, trading at $183.50, which reflects a 25.5% gain from recent lows. Despite this short-term success driven by solid quarterly results, analysts advise caution and recommend avoiding the stock in the current portfolio due to concerns about its long-term quality. The article highlights that Biogen's demand has been weak over the last five years, with sales declining at a 6% annual rate, which falls below the company's investment standards for sustained growth. This lack of revenue growth suggests diminishing business quality despite recent price appreciation. Beyond revenue issues, Biogen's financial metrics further support the recommendation to avoid it. Earnings per share (EPS) have declined by 14.2% annually over the last five years, outpacing the rate of revenue decline and indicating that the company's fixed cost base is difficult to adjust to shrinking demand. Additionally, Return on Invested Capital (ROIC), a key metric for measuring operating profit relative to capital raised, has decreased significantly in recent years. This declining trend suggests that management may be facing fewer profitable growth opportunities, further undermining confidence in the company's future prospects despite its past operational efforts. The analysts maintain that Biogen does not meet their internal quality test and possess little faith in its future performance compared to other investment options. Although the stock currently trades at a 11.3× forward P/E multiple, which is considered fair valuations, the firm lacks confidence in the company's ability to sustain growth. Instead of investing in Biogen, the article points readers toward their digital advertising picks and introduces a broader service called StockStory. This service uses an AI system to identify top-performing stocks, having previously flagged companies like Palantir, AppLovin, and Nvidia before they delivered substantial multi-year gains ranging from 753% to 1,662%.